Adia Med Inc.ADIA
Key ratios
FCF / Sales
-27.5%2025
2024
-5583.7%
Net margin
-23.7%TTM
2025
-56.5%
ROA
-36.1%2025
2024
-32.8%
ROE
-1460.8%TTM
2024
-1460.8%
Revenue growth
10879.8%2025
Recent news
Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment
From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team
Adia Med Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Track ADIA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer